Polypeptide Laboratories A/S
A/SActiveCVR 19056201Herredsvejen 2, 3400 HillerødOther financial service activities, except insurance and pension funding n.e.c.· NACE 6499Est. 1996 · 30 years old0 employees
Loading company…
Overview
Polypeptide Laboratories A/S is a Danish A/S based in Hillerød, operating in the Other financial service activities, except insurance and pension funding n.e.c. sector. Incorporated in 1996, the company has 0 employees.
Gross profit 2025
—
EBITDA margin
—
Net profit 2025
2.6M DKK
-63% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
100.0 %
Very strongAmong the 10% highest rated companies in the industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
>999×
Very strongAmong the 10% highest rated companies in the industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
3.5 %
AverageAround the average of companies in the same industry
20212025
EBITDA — year on year
DKK thousandsKey figures
Annual report 2025| Gross profit | — | — |
| EBITDA | -0.1M DKK | -39% |
| Net profit | 2.6M DKK | -63% |
| Total assets | 75.5M DKK | +4% |
| Equity | 75.5M DKK | +4% |
| Employees | 0 | — |
Company information
Legal name
POLYPEPTIDE LABORATORIES A/S
CVR number
19056201
Legal form
Aktieselskab
Founded
1 January 1996 · 30 years
Share capital
DKK 20,000,000
Employees
0 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et bestyrelsesmedlem eller af et bestyrelsesmedlem i forening med en direktør
Company purpose
Selskabets formål er fabrikation og handel samt at drive virksomhed på områderne udvikling, produktion, distribution og salg af peptider
(no translation available)
Contact
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of DKK 2.6m.
At the end of 2025, equity financed 100% of the balance sheet, and current assets covered short-term debt 3,775.9 times.
Financials
Gross profit
DKKNo figures reported for this period.
EBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross profit | — | — | — | — | — |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -50 | -36 | -65 | -39 | -61 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -50 | -36 | -65 | -39 | -61 |
| Net financials | 3,424 | 4,273 | 3,294 | -2,994 | -778 |
| Profit before tax | 3,374 | 4,237 | 3,229 | -3,033 | -839 |
| Tax | 742 | -2,823 | -0 | -0 | -0 |
| Net profit | 2,632 | 7,060 | 3,229 | -3,033 | -839 |
Balance sheet
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 75,519 | 72,888 | 65,843 | 62,614 | 65,657 |
| Equity | 75,499 | 72,867 | 65,807 | 62,578 | 65,611 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 20 | 21 | 36 | 36 | 46 |
| Total debt | 20 | 21 | 36 | 36 | 46 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
<−999 %
20212025
Equity ratio
100.0 %
Very strongAmong the 10% highest rated companies in the industry
20212025
Return on equity
3.5 %
AverageAround the average of companies in the same industry
20212025
Net profit margin (of gross profit)
>999 %
20212025
Asset turnover (of gross profit)
0.00×
20212025
Debt / equity
0.00×
Very strongAmong the 10% highest rated companies in the industry
20212025
Sector performance
21 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Average
Around the average of companies in the same industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Average
Around the average of companies in the same industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Strong
Among the 40% highest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioVery strong
Among the 10% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioVery strong
Among the 10% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery weak
Among the 10% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityWeak
Among the 40% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 10% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioWeak
Among the 40% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioVery strong
Among the 10% highest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery strong
Among the 10% highest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityVery strong
Among the 10% highest rated companies in the industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityVery strong
Among the 10% highest rated companies in the industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtVery strong
Among the 10% highest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 10% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest rate on debtVery strong
Among the 10% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginStrong
Among the 40% highest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Interest coverageNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The ability to pay the interest on the company's debt out of its earnings.
Efficiency & development
Equity to contributed capitalWeak
Among the 40% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityStrong
Among the 40% highest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtStrong
Among the 40% highest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RB Management | Management | 2026 |
Former (11)
MF Management | Management | 2025 – 2026 |
JM Management | Management | 2021 – 2023 |
AS Chief Executive Officer | Chief Executive Officer | 2008 – 2013 |
ET Management | Management | 1996 – 2003 |
JF Chief Executive Officer | Chief Executive Officer | 2013 – 2021 |
PE Management | Management | 1996 – 1996 |
AJ Management | Management | 1996 – 2001 |
ET | Audit | 1996 – 1996 |
JJ Management | Management | 2023 – 2025 |
ES Audit | Audit | 1996 – 1998 |
JF Management | Management | 2003 – 2007 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
RB Board of Directors | Board of Directors | 2026 |
JJ Chairman | Chairman | 2025 |
CE Board of Directors | Board of Directors | 2023 |
Former (18)
MF Board of Directors | Board of Directors | 2025 – 2026 |
JM Board of Directors | Board of Directors | 2016 – 2023 |
US Chairman | Chairman | 1996 – 1996 |
AS Board of Directors | Board of Directors | 2008 – 2016 |
ET Board of Directors | Board of Directors | 1996 – 2003 |
JF Board of Directors | Board of Directors | 2021 – 2025 |
ML Board of Directors | Board of Directors | 1996 – 1998 |
PE Board of Directors | Board of Directors | 1996 – 1996 |
LG Board of Directors | Board of Directors | 2003 – 2016 |
OK Board of Directors | Board of Directors | 1996 – 2003 |
FF Board of Directors | Board of Directors | 2016 – 2021 |
EW Board of Directors | Board of Directors | 1996 – 1996 |
DG Board of Directors | Board of Directors | 2021 – 2021 |
JA Chairman | Chairman | 2003 – 2021 |
RD Chairman | Chairman | 2021 – 2023 |
DF Board of Directors | Board of Directors | 1996 – 2001 |
JF Board of Directors | Board of Directors | 2001 – 2008 |
HC Board of Directors | Board of Directors | 1996 – 1996 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
PolyPeptide Laboratories Holding (PPL) AB | Company | 100% | 100% | 2021 |
PolyPeptide Laboratories BV | Company | 100% | 100% | 1996 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Related companies
Company hierarchy
PolyPeptide Laboratories Holding (PPL) AB100%PolyPeptide Laboratories BV100%
Polypeptide Laboratories A/S (this company)Board network connections
Board members of Polypeptide Laboratories A/S also hold positions in 255 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Emil Hasselbalch Stakemann | Management | 236 companiesMany roles |
| Hans Christian Galst | Board of Directors | 11 companiesMany roles |
| Ulf Svejgaard Poulsen | Chairman | 3 companies |
| Erik Tronborg Andersen | Audit | 2 companies |
| Jan Miller | Management | 1 company |
| Erling Stæhr Lohse | Audit | 1 company |
| Dag Frederik Arfst Paulsen | Board of Directors | 1 company |
Frequently asked questions
What is the CVR number of Polypeptide Laboratories A/S?
Polypeptide Laboratories A/S is registered with CVR / Virk under CVR 19056201.
Who is the chairman of Polypeptide Laboratories A/S?
Juan José Gonzalez Casanova chairs the board of Polypeptide Laboratories A/S, in role since 2025.
Where is Polypeptide Laboratories A/S headquartered?
Polypeptide Laboratories A/S's registered address is Herredsvejen 2.